InnoBioSurg Co.,Ltd is categorized under Business Services (Unclassified) in Represa, CA and active since 2008.
InnoBioSurg Co.,Ltd was established in 2008, and today employs 1 to 4, earning Unknown per year. This is a Business Services (Unclassified) business, which does work in the B2B market, and is classified as a Business Services (Unclassified), under code number by the NAICS.
If you are seeking more information, feel free to contact Tom Lee Full Name Report at the company’s single location by writing to 1st floor, 518, Yongsandong, Yuseong-gu,
Daejeon City, Republic of Korea, Represa, California CA 95671 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
|Business Name:||InnoBioSurg Co.,Ltd|
|Contact Person:||Tom Lee Full Name Report|
|Address:||1st floor, 518, Yongsandong, Yuseong-gu,
Daejeon City, Republic of Korea, Represa, California 95671
|Annual Revenue (USD):||Unknown|
|Location Type:||Single Location|
|Employee Number:||1 to 4|
|Business Type:||B2B (Business to Business)|
|Business Category:||Business Services (Unclassified)|
|Share This Business:|
InnoBioSurg Co.,Ltd was started in 2008 to provide professional Business Services (Unclassified) under the SIC code and NAICS code . Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Tom Lee Full Name Report for inquiries that concern InnoBioSurg Co.,Ltd by calling the company number No number given, as your correspondence is most welcome.
Additionally, the physical location of the single location of InnoBioSurg Co.,Ltd can be found at the coordinates 38.626708984375,-121.26 as well as the street address 1st floor, 518, Yongsandong, Yuseong-gu,
Daejeon City, Republic of Korea in Represa, California 95671.
For its online presence, you may visit InnoBioSurg Co.,Ltd’s website at ibsimplant.com and engage with its social media outlets through on Twitter and on Facebook.